{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:02:48Z","timestamp":1790996568920,"version":"4.1.0"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Behavioural Brain Research"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.bbr.2024.115173","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T04:14:25Z","timestamp":1722658465000},"page":"115173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Targeting NMDA receptors with an antagonist is a promising therapeutic strategy for treating neurological disorders"],"prefix":"10.1016","volume":"472","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4200-861X","authenticated-orcid":false,"given":"Md. Rajdoula","family":"Rafe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranoy","family":"Saha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Temitayo","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.bbr.2024.115173_bib1","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1111\/j.1471-4159.2006.03991.x","article-title":"The chemical biology of clinically tolerated NMDA receptor antagonists","volume":"97","author":"Chen","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbr.2024.115173_bib2","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10072-016-2546-5","article-title":"Dysfunction of NMDA receptors in Alzheimer\u2019s disease","volume":"37","author":"Zhang","year":"2016","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.bbr.2024.115173_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neuroscience.2013.01.075","article-title":"Okadaic acid-induced Tau phosphorylation in rat brain: role of NMDA receptor","volume":"238","author":"Kamat","year":"2013","journal-title":"Neuroscience"},{"issue":"9","key":"10.1016\/j.bbr.2024.115173_bib4","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.tins.2008.06.005","article-title":"Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease","volume":"31","author":"Bezprozvanny","year":"2008","journal-title":"Trends Neurosci."},{"issue":"3","key":"10.1016\/j.bbr.2024.115173_bib5","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1056\/NEJMcibr0902052","article-title":"Memory and the NMDA receptors","volume":"361","author":"Li","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bbr.2024.115173_bib6","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/scientificamerican0400-62","article-title":"Building a brainier mouse","volume":"282","author":"Tsien","year":"2000","journal-title":"Sci. Am."},{"issue":"6","key":"10.1016\/j.bbr.2024.115173_bib7","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1460-9568.2007.05431.x","article-title":"Maintenance of superior learning and memory function in NR2B transgenic mice during ageing","volume":"25","author":"Cao","year":"2007","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbr.2024.115173_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.neuropharm.2013.03.030","article-title":"NMDA receptors in nervous system diseases","volume":"74","author":"Zhou","year":"2013","journal-title":"Neuropharmacology"},{"issue":"255","key":"10.1016\/j.bbr.2024.115173_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/stke.2552004re16","article-title":"Role of distinct NMDA receptor subtypes at central synapses","volume":"2004","author":"Cull-Candy","year":"2004","journal-title":"Sci. 'S. STKE"},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.coph.2006.08.011","article-title":"NMDA receptor subunits: function and pharmacology","volume":"7","author":"Paoletti","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"issue":"3","key":"10.1016\/j.bbr.2024.115173_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1124\/pr.109.002451","article-title":"Glutamate receptor ion channels: structure, regulation, and function","volume":"62","author":"Traynelis","year":"2010","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.bbr.2024.115173_bib12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1113\/JP280875","article-title":"Positive allosteric modulation of NMDA receptors: mechanisms, physiological impact and therapeutic potential","volume":"600","author":"Geoffroy","year":"2022","journal-title":"J. Physiol."},{"issue":"8","key":"10.1016\/j.bbr.2024.115173_bib13","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1111\/j.1460-9568.2011.07628.x","article-title":"Molecular basis of NMDA receptor functional diversity","volume":"33","author":"Paoletti","year":"2011","journal-title":"Eur. J. Neurosci."},{"issue":"10","key":"10.1016\/j.bbr.2024.115173_bib14","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1113\/JP279028","article-title":"Architecture and function of NMDA receptors: an evolutionary perspective","volume":"599","author":"Stroebel","year":"2021","journal-title":"J. Physiol."},{"issue":"7065","key":"10.1016\/j.bbr.2024.115173_bib15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nature04089","article-title":"Subunit arrangement and function in NMDA receptors","volume":"438","author":"Furukawa","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2024.115173_bib16","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.neuroscience.2015.10.033","article-title":"Presynaptic NMDA receptors: roles and rules","volume":"311","author":"Bouvier","year":"2015","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.tins.2015.11.001","article-title":"Roles of presynaptic NMDA receptors in neurotransmission and plasticity","volume":"39","author":"Banerjee","year":"2016","journal-title":"Trends Neurosci."},{"issue":"2","key":"10.1016\/j.bbr.2024.115173_bib18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1523\/JNEUROSCI.07-02-00369.1987","article-title":"Ionic dependence of glutamate neurotoxicity","volume":"7","author":"Choi","year":"1987","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbr.2024.115173_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105613","article-title":"Traumatic brain injury in women across lifespan","volume":"164","author":"Blaya","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbr.2024.115173_bib20","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11515-011-1187-6","article-title":"NMDA receptor signaling: death or survival?","volume":"6","author":"Luo","year":"2011","journal-title":"Front. Biol."},{"issue":"5594","key":"10.1016\/j.bbr.2024.115173_bib21","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1126\/science.1072873","article-title":"Treatment of ischemic brain damage by perturbing NMDA receptor-PSD-95 protein interactions","volume":"298","author":"Aarts","year":"2002","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.neuropharm.2007.04.015","article-title":"Excitotoxicity in vitro by NR2A-and NR2B-containing NMDA receptors","volume":"53","author":"von Engelhardt","year":"2007","journal-title":"Neuropharmacology"},{"issue":"11","key":"10.1016\/j.bbr.2024.115173_bib23","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1523\/JNEUROSCI.0116-07.2007","article-title":"NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo","volume":"27","author":"Liu","year":"2007","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.bbr.2024.115173_bib24","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.cell.2009.12.055","article-title":"DAPK1 interaction with NMDA receptor NR2B subunits mediates brain damage in stroke","volume":"140","author":"Tu","year":"2010","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.bbr.2024.115173_bib25","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.tins.2008.06.005","article-title":"Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease","volume":"31","author":"Bezprozvanny","year":"2008","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.bbr.2024.115173_bib26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fncel.2015.00245","article-title":"NMDA receptor GluN2A\/GluN2B subunit ratio as synaptic trait of levodopa-induced dyskinesias: from experimental models to patients","volume":"9","author":"Mellone","year":"2015","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.bbr.2024.115173_bib27","first-page":"165","article-title":"Changes in surface expression of N-methyl-D-aspartate receptors in the striatum in a rat model of Parkinson\u2019s disease.","author":"Gan","year":"2014","journal-title":"Drug Des., Dev. Ther."},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib28","article-title":"A NMDA-receptor calcium influx assay sensitive to stimulation by glutamate and glycine\/D-serine","volume":"7","author":"Guo","year":"2017","journal-title":"Sci. Rep."},{"issue":"18","key":"10.1016\/j.bbr.2024.115173_bib29","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.3390\/ijms20184391","article-title":"Roles of glutamate receptors in Parkinson\u2019s disease","volume":"20","author":"Zhang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.bbr.2024.115173_bib30","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1358\/dnp.1998.11.9.863689","article-title":"Glutamate in CNS disorders as a target for drug development: an update","volume":"11","author":"Parsons","year":"1998","journal-title":"Drug N. Perspect."},{"issue":"1-3","key":"10.1016\/j.bbr.2024.115173_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0014-2999(01)01307-3","article-title":"NMDA receptors as targets for drug action in neuropathic pain","volume":"429","author":"Parsons","year":"2001","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbr.2024.115173_bib32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","article-title":"Rationale for and use of NMDA receptor antagonists in Parkinson's disease","volume":"102","author":"Hallett","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbr.2024.115173_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.coph.2005.12.002","article-title":"Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists","volume":"6","author":"Muir","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"issue":"12","key":"10.1016\/j.bbr.2024.115173_bib34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.tips.2011.08.003","article-title":"New advances in NMDA receptor pharmacology","volume":"32","author":"Ogden","year":"2011","journal-title":"Trends Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.bbr.2024.115173_bib35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/jnc.14970","article-title":"Regulation of NMDA glutamate receptor functions by the GluN2 subunits","volume":"154","author":"Vieira","year":"2020","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbr.2024.115173_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108840","article-title":"Differential regulation of STP, LTP and LTD by structurally diverse NMDA receptor subunit-specific positive allosteric modulators","volume":"202","author":"France","year":"2022","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib37","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41467-023-37260-y","article-title":"Two gates mediate NMDA receptor activity and are under subunit-specific regulation","volume":"14","author":"Amin","year":"2023","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bbr.2024.115173_bib38","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.bbr.2024.115173_bib39","series-title":"Stuttgart","first-page":"253","article-title":"Extrasynaptic NMDA receptors: mediators of excitotoxic cell death. Pharmacology of Cerebral Ischemia","author":"Wittmann","year":"2004"},{"issue":"2","key":"10.1016\/j.bbr.2024.115173_bib40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neuron.2014.03.030","article-title":"Extrasynaptic NMDA receptor involvement in central nervous system disorders","volume":"82","author":"Parsons","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.bbr.2024.115173_bib41","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nrn3531","article-title":"Nuclear calcium signalling in the regulation of brain function","volume":"14","author":"Bading","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.bbr.2024.115173_bib42","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hipo.20383","article-title":"Long-term potentiation inhibition by low-level N-methyl-D-aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen-activated protein kinase","volume":"18","author":"Izumi","year":"2008","journal-title":"Hippocampus"},{"key":"10.1016\/j.bbr.2024.115173_bib43","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.0953-816x.2001.01664.x","article-title":"Requirement of appropriate glutamate concentrations in the synaptic cleft for hippocampal LTP induction","volume":"14","author":"Katagiri","year":"2001","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.bbr.2024.115173_bib44","doi-asserted-by":"crossref","first-page":"6627","DOI":"10.1523\/JNEUROSCI.0203-11.2011","article-title":"Soluble Ab oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors","volume":"31","author":"Li","year":"2011","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.bbr.2024.115173_bib45","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1161\/STROKEAHA.122.036946","article-title":"Neuroinflammation, stroke, blood-brain barrier dysfunction, and imaging modalities","volume":"53","author":"Candelario-Jalil","year":"2022","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.bbr.2024.115173_bib46","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.molmed.2020.03.001","article-title":"NMDARs in cell survival and death: implications in stroke pathogenesis and treatment","volume":"26","author":"Ge","year":"2020","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbr.2024.115173_bib47","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.neuint.2019.04.016","article-title":"Bis (propyl)-cognitin potentiates rehabilitation of treadmill exercise after a transient focal cerebral ischemia, possibly via inhibiting NMDA receptor and regulating VEGF expression","volume":"128","author":"Ke","year":"2019","journal-title":"Neurochem. Int."},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib48","article-title":"Determining the effect of aging, recovery time, and post-stroke memantine treatment on delayed thalamic gliosis after cortical infarct","volume":"11","author":"Kim","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbr.2024.115173_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jnutbio.2022.109209","article-title":"Folic acid ameliorates synaptic impairment following cerebral ischemia\/reperfusion injury via inhibiting excessive activation of NMDA receptors","volume":"112","author":"Liang","year":"2023","journal-title":"J. Nutr. Biochem."},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib50","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.neulet.2011.10.045","article-title":"Addition of NMDA-receptor antagonist MK801 during oxygen\/glucose deprivation moderately attenuates the upregulation of glucose uptake after subsequent reoxygenation in brain endothelial cells","volume":"506","author":"Neuhaus","year":"2012","journal-title":"Neurosci. Lett."},{"issue":"7","key":"10.1016\/j.bbr.2024.115173_bib51","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3390\/biomedicines11071885","article-title":"The Role of NMDA Receptor Partial Antagonist, Carbamathione, as a Therapeutic Agent for Transient Global Ischemia","volume":"11","author":"Modi","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.bbr.2024.115173_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113876","article-title":"Discovery of novel brain-penetrant GluN2B NMDAR antagonists via pharmacophore-merging strategy as anti-stroke therapeutic agents","volume":"227","author":"Xu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bbr.2024.115173_bib53","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s11055-010-9292-6","article-title":"Use of the glutamate NMDA receptor antagonist PK-Merz in acute stroke","volume":"40","author":"Krivonos","year":"2010","journal-title":"Neurosci. Behav. Physiol."},{"issue":"2","key":"10.1016\/j.bbr.2024.115173_bib54","first-page":"1213","article-title":"BQ-869, a novel NMDA receptor antagonist, protects against excitotoxicity and attenuates cerebral ischemic injury in stroke","volume":"8","author":"Yu","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"5","key":"10.1016\/j.bbr.2024.115173_bib55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1742-7843.2007.00127.x","article-title":"Combination Therapy of Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-\u03b3 Ligand, and NMDA Receptor Antagonist (MK-801) on Experimental Embolic Stroke in Rats","volume":"101","author":"Allahtavakoli","year":"2007","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"2","key":"10.1016\/j.bbr.2024.115173_bib56","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000503831","article-title":"The epidemiology of epilepsy","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"issue":"4","key":"10.1016\/j.bbr.2024.115173_bib57","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.0013-9580.2005.66104.x","article-title":"Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)","volume":"46","author":"Fisher","year":"2005","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.bbr.2024.115173_bib58","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3390\/ph15101297","article-title":"Targeting NMDA receptor complex in management of epilepsy","volume":"15","author":"Sivakumar","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"11","key":"10.1016\/j.bbr.2024.115173_bib59","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1111\/j.1460-9568.1993.tb00224.x","article-title":"Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy","volume":"5","author":"L\u00f6scher","year":"1993","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/j.bbr.2024.115173_bib60","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.yebeh.2010.04.002","article-title":"Voltage-dependent calcium channel and NMDA receptor antagonists augment anticonvulsant effects of lithium chloride on pentylenetetrazole-induced clonic seizures in mice","volume":"18","author":"Ghasemi","year":"2010","journal-title":"Epilepsy Behav."},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib61","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.eplepsyres.2010.06.010","article-title":"Inhibition of NMDA receptor\/NO signaling blocked tolerance to the anticonvulsant effect of morphine on pentylenetetrazole-induced seizures in mice","volume":"91","author":"Ghasemi","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.bbr.2024.115173_bib62","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.brainresbull.2016.01.013","article-title":"NMDA receptor antagonists attenuate the proconvulsant effect of juvenile social isolation in male mice","volume":"121","author":"Amiri","year":"2016","journal-title":"Brain Res. Bull."},{"issue":"3","key":"10.1016\/j.bbr.2024.115173_bib63","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.acthis.2018.02.004","article-title":"Non-competitive antagonists of NMDA and AMPA receptors decrease seizure-induced c-fos protein expression in the cerebellum and protect against seizure symptoms in adult rats","volume":"120","author":"T\u00f3th","year":"2018","journal-title":"Acta Histochem."},{"issue":"3","key":"10.1016\/j.bbr.2024.115173_bib64","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.pharep.2013.12.007","article-title":"Orphenadrine-induced convulsive status epilepticus in rats responds to the NMDA antagonist dizocilpine","volume":"66","author":"Rejdak","year":"2014","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.bbr.2024.115173_bib65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00178973","article-title":"The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents","volume":"342","author":"Schmutz","year":"1990","journal-title":"Naunyn-Schmiede 'S. Arch. Pharmacol."},{"issue":"9","key":"10.1016\/j.bbr.2024.115173_bib66","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamaneurol.2022.2189","article-title":"Global prevalence and incidence of tinnitus: a systematic review and meta-analysis","volume":"79","author":"Jarach","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bbr.2024.115173_bib67","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neubiorev.2013.03.021","article-title":"An integrative model of auditory phantom perception: tinnitus as a unified percept of interacting separable subnetworks","volume":"44","author":"De Ridder","year":"2014","journal-title":"Neurosci. Biobehav Rev."},{"issue":"10","key":"10.1016\/j.bbr.2024.115173_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0077674","article-title":"Local NMDA receptor blockade attenuates chronic tinnitus and associated brain activity in an animal model","volume":"8","author":"Brozoski","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbr.2024.115173_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2007\/80904","article-title":"Blockade of cochlear NMDA receptors prevents long-term tinnitus during a brief consolidation window after acoustic trauma","volume":"2007","author":"Guitton","year":"2007","journal-title":"Neural Plast."},{"key":"10.1016\/j.bbr.2024.115173_bib70","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00405-009-1126-1","article-title":"Effects of extracochlear gacyclidine perfusion on tinnitus in humans: a case series","volume":"267","author":"Wenzel","year":"2010","journal-title":"Eur. Arch. oto-rhino-Laryngol."},{"issue":"5","key":"10.1016\/j.bbr.2024.115173_bib71","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1159\/000374000","article-title":"Cochlear NMDA receptors as a therapeutic target of noise-induced tinnitus","volume":"35","author":"Bing","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"issue":"4","key":"10.1016\/j.bbr.2024.115173_bib72","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/MAO.0000000000000268","article-title":"Efficacy and safety of AM-101 in the treatment of acute inner ear tinnitus\u2014a double-blind, randomized, placebo-controlled phase II study","volume":"35","author":"Van de Heyning","year":"2014","journal-title":"Otol. Neurotol."},{"key":"10.1016\/j.bbr.2024.115173_bib73","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00415-005-0814-z","article-title":"An overview of the patient with ataxia","volume":"252","author":"Mariotti","year":"2005","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.bbr.2024.115173_bib74","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0883073812441999","article-title":"Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate","volume":"28","author":"Nissenkorn","year":"2013","journal-title":"J. Child Neurol."},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14802\/jmd.12001","article-title":"Preliminary study of intravenous amantadine treatment for ataxia management in patients with probable multiple system atrophy with predominant cerebellar ataxia","volume":"5","author":"Youn","year":"2012","journal-title":"J. Mov. Disord."},{"key":"10.1016\/j.bbr.2024.115173_bib76","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.neulet.2015.02.055","article-title":"Long-term oral administration of the NMDA receptor antagonist memantine extends life span in spinocerebellar ataxia type 1 knock-in mice","volume":"592","author":"Iizuka","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.bbr.2024.115173_bib77","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fnins.2019.00043","article-title":"The role of NMDA receptors in Alzheimer\u2019s disease","volume":"13","author":"Liu","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bbr.2024.115173_bib78","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2013.08.013","article-title":"Dysfunctional synapse in Alzheimer's disease\u2013A focus on NMDA receptors","volume":"76","author":"Mota","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2024.115173_bib79","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10072-016-2546-5","article-title":"Dysfunction of NMDA receptors in Alzheimer\u2019s disease","volume":"37","author":"Zhang","year":"2016","journal-title":"Neurol. Sci."},{"issue":"S1","key":"10.1016\/j.bbr.2024.115173_bib80","doi-asserted-by":"crossref","DOI":"10.1177\/0091270006288735","article-title":"Rationale for combination therapy with galantamine and memantine in Alzheimer's disease","volume":"46","author":"Grossberg","year":"2006","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bbr.2024.115173_bib81","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00002018-200831070-00003","article-title":"Memantine for the treatment of Alzheimer\u2019s disease: tolerability and safety data from clinical trials","volume":"31","author":"Farlow","year":"2008","journal-title":"Drug Saf."},{"issue":"10291","key":"10.1016\/j.bbr.2024.115173_bib82","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41398-018-0162-2","article-title":"NMDA antagonists for treating the non-motor symptoms in Parkinson\u2019s disease","volume":"8","author":"Vanle","year":"2018","journal-title":"Transl. Psychiatry"},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib84","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.expneurol.2004.01.018","article-title":"Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease","volume":"187","author":"L\u00f6schmann","year":"2004","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbr.2024.115173_bib85","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF02260076","article-title":"Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease","volume":"4","author":"Rabey","year":"1992","journal-title":"J. Neural Transm. -Park. 'S. Dis. Dement. Sect."},{"issue":"4","key":"10.1016\/j.bbr.2024.115173_bib86","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0149-7634(96)00037-1","article-title":"Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents\u2014preclinical studies","volume":"21","author":"Danysz","year":"1997","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bbr.2024.115173_bib87","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.brainresbull.2020.12.011","article-title":"Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease","volume":"168","author":"Vecchia","year":"2021","journal-title":"Brain Res. Bull."},{"issue":"6","key":"10.1016\/j.bbr.2024.115173_bib88","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3390\/cells12060853","article-title":"Current advancements in spinal cord injury research\u2014glial scar formation and neural regeneration","volume":"12","author":"Clifford","year":"2023","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.bbr.2024.115173_bib89","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/01616412.1996.11740463","article-title":"Pretreatment with NMDA receptor antagonist MK801 improves neurophysiological outcome after an acute spinal cord injury","volume":"18","author":"Haghighi","year":"1996","journal-title":"Neurol. Res."},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib90","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0006-8993(99)02483-X","article-title":"Intrathecal administration of an NMDA or a non-NMDA receptor antagonist reduces mechanical but not thermal allodynia in a rodent model of chronic central pain after spinal cord injury","volume":"859","author":"Bennett","year":"2000","journal-title":"Brain Res."},{"issue":"5","key":"10.1016\/j.bbr.2024.115173_bib91","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.pain.2012.02.003","article-title":"Effect of NMDA NR2B antagonist on neuropathic pain in two spinal cord injury models","volume":"153","author":"Kim","year":"2012","journal-title":"PAIN"},{"issue":"8","key":"10.1016\/j.bbr.2024.115173_bib92","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1002\/ejp.1795","article-title":"Amantadine prevented hypersensitivity and decreased oxidative stress by NMDA receptor antagonism after spinal cord injury in rats","volume":"25","author":"Mata-Bermudez","year":"2021","journal-title":"Eur. J. Pain."},{"issue":"2","key":"10.1016\/j.bbr.2024.115173_bib93","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0006-8993(00)02581-6","article-title":"Neuroprotective effects of a novel NMDA antagonist, Gacyclidine, after experimental contusive spinal cord injury in adult rats","volume":"874","author":"Gaviria","year":"2000","journal-title":"Brain Res."},{"issue":"14","key":"10.1016\/j.bbr.2024.115173_bib94","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1097\/00001756-200009280-00031","article-title":"Agmatine improves locomotor function and reduces tissue damage following spinal cord injury","volume":"11","author":"Yu","year":"2000","journal-title":"Neuroreport"},{"issue":"2-3","key":"10.1016\/j.bbr.2024.115173_bib95","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0304-3959(97)00189-9","article-title":"The NMDA-receptor antagonist ketamine abolishes neuropathic pain after epidural administration in a clinical case","volume":"75","author":"Takahashi","year":"1998","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib96","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev.ne.17.030194.000335","article-title":"Cloned glutamate receptors","volume":"17","author":"Hollmann","year":"1994","journal-title":"Annu. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib97","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1146\/annurev.pharmtox.37.1.205","article-title":"Pharmacology and functions of metabotropic glutamate receptors","volume":"37","author":"Conn","year":"1997","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib98","first-page":"7","article-title":"The glutamate receptor ion channels","volume":"51","author":"Dingledine","year":"1999","journal-title":"Pharmacol. Rev."},{"issue":"2","key":"10.1016\/j.bbr.2024.115173_bib99","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pharmthera.2004.04.001","article-title":"Rationale for and use of NMDA receptor antagonists in Parkinson's disease","volume":"102","author":"Hallett","year":"2004","journal-title":"Pharmacol. Ther."},{"issue":"8","key":"10.1016\/j.bbr.2024.115173_bib100","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3390\/biom10081134","article-title":"Is Memantine Effective as an NMDA Receptor Antagonist in Adjunctive Therapy for Schizophrenia?","volume":"10","author":"Kikuchi","year":"2020","journal-title":"Biomolecules"},{"key":"10.1016\/j.bbr.2024.115173_bib101","first-page":"9","article-title":"Critical appraisal and role of memantine extended-release in the management of Alzheimer\u2019s disease.","author":"Singh","year":"2011","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"issue":"7871","key":"10.1016\/j.bbr.2024.115173_bib102","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41586-021-03769-9","article-title":"Structural basis of ketamine action on human NMDA receptors","volume":"596","author":"Zhang","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.bbr.2024.115173_bib103","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1176\/appi.ajp.2020.20010018","article-title":"Efficacy of intravenous ketamine in adolescent treatment-resistant depression: a randomized midazolam-controlled trial","volume":"178","author":"Dwyer","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"13","key":"10.1016\/j.bbr.2024.115173_bib104","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1523\/JNEUROSCI.4262-04.2005","article-title":"Amantadine inhibits NMDA receptors by accelerating channel closure during channel block","volume":"25","author":"Blanpied","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbr.2024.115173_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113443","article-title":"Involvement of dopamine D2 and glutamate NMDA receptors in the antidepressant-like effect of amantadine in mice","volume":"413","author":"Raupp-Barcaro","year":"2021","journal-title":"Behav. Brain Res."},{"issue":"4","key":"10.1016\/j.bbr.2024.115173_bib106","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1177\/1352458518754716","article-title":"Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial","volume":"25","author":"Cohen","year":"2019","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.bbr.2024.115173_bib107","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fncel.2013.00280","article-title":"Gacyclidine improves the survival and reduces motor deficits in a mouse model of amyotrophic lateral sclerosis","volume":"7","author":"Gerber","year":"2013","journal-title":"Front. Cell. Neurosci."},{"issue":"2-3","key":"10.1016\/j.bbr.2024.115173_bib108","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0028-3770(21)00116-8","article-title":"D'ARBIGNY P, Mathe JF, Vigue B, Loubert G, Delcour J, Kempf C, Tadie M. Neuroprotective effect of gacyclidine: A multicenter double-blind pilot trial in patients with acute traumatic brain injury","volume":"50","author":"Lepeintre","year":"2004","journal-title":"Neurochirurgie"},{"issue":"2","key":"10.1016\/j.bbr.2024.115173_bib109","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1021\/acs.jmedchem.0c01912","article-title":"Ifenprodil stereoisomers: synthesis, absolute configuration, and correlation with biological activity","volume":"64","author":"Bechthold","year":"2021","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bbr.2024.115173_bib110","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/npr2.12232","article-title":"Ifenprodil for the treatment of methamphetamine use disorder: An exploratory, randomized, double-blind, placebo-controlled trial","volume":"42","author":"Kotajima-Murakami","year":"2022","journal-title":"Neuropsychopharmacol. Rep."},{"issue":"12","key":"10.1016\/j.bbr.2024.115173_bib111","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1007\/s00213-023-06454-z","article-title":"MK-801 and cognitive functions: Investigating the behavioral effects of a non-competitive NMDA receptor antagonist","volume":"240","author":"Janus","year":"2023","journal-title":"Psychopharmacology"},{"issue":"1-2","key":"10.1016\/j.bbr.2024.115173_bib112","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0006-8993(92)90814-P","article-title":"The effect of the NMDA receptor antagonist MK-801 on cerebral blood flow and infarct volume in experimental focal stroke","volume":"574","author":"Buchan","year":"1992","journal-title":"Brain Res."},{"issue":"11","key":"10.1016\/j.bbr.2024.115173_bib113","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.4103\/1673-5374.259619","article-title":"MK-801 attenuates lesion expansion following acute brain injury in rats: a meta-analysis","volume":"14","author":"Yi","year":"2019","journal-title":"Neural Regen. Res."},{"issue":"6","key":"10.1016\/j.bbr.2024.115173_bib114","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/HRP.0000000000000183","article-title":"Glutamatergic modulators in depression","volume":"26","author":"Henter","year":"2018","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.bbr.2024.115173_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2022.114867","article-title":"Efficacy and safety of nitrous oxide for patients with treatment-resistant depression, a randomized controlled trial","volume":"317","author":"Yan","year":"2022","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.bbr.2024.115173_bib116","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1007\/s00213-019-05310-3","article-title":"NMDA receptor antagonists traxoprodil and lanicemine improve hippocampal-prefrontal coupling and reward-related networks in rats","volume":"236","author":"Becker","year":"2019","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.bbr.2024.115173_bib117","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1089\/neu.2005.22.1428","article-title":"The effect of the selective NMDA receptor antagonist traxoprodil in the treatment of traumatic brain injury","volume":"22","author":"Yurkewicz","year":"2005","journal-title":"J. Neurotrauma"},{"issue":"2","key":"10.1016\/j.bbr.2024.115173_bib118","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/aps.2015.111","article-title":"Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in mice","volume":"37","author":"Zhang","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"issue":"9","key":"10.1016\/j.bbr.2024.115173_bib119","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/mp.2013.130","article-title":"Lanicemine: a low-trapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects","volume":"19","author":"Sanacora","year":"2014","journal-title":"Mol. Psychiatry"},{"issue":"11","key":"10.1016\/j.bbr.2024.115173_bib120","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/da.23194","article-title":"Vo-Le B, O\u2032Brien B, Murrough JW, Swann AC. Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial","volume":"38","author":"Ramakrishnan","year":"2021","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.bbr.2024.115173_bib121","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.neuropharm.2018.07.021","article-title":"The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta (A\u03b2) species on long-term potentiation (LTP)","volume":"140","author":"Rammes","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bbr.2024.115173_bib122","doi-asserted-by":"crossref","unstructured":"Bertocchi I., Cifarelli L., Oberto A., Eva C.E., Sprengel R., Mirza N.R., Muglia P. Radiprodil, a selective GluN2B negative allosteric modulator, rescues audiogenic seizures in mice carrying the GluN2A (N615S) mutation. British Journal of Pharmacology. 2023 Jul 25.","DOI":"10.22541\/au.169028585.52171833\/v1"},{"issue":"3","key":"10.1016\/j.bbr.2024.115173_bib123","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/acn3.50998","article-title":"Radiprodil, a NR2B negative allosteric modulator, from bench to bedside in infantile spasm syndrome","volume":"7","author":"Auvin","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"9","key":"10.1016\/j.bbr.2024.115173_bib124","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1358\/dnp.2010.23.9.1513493","article-title":", an NR2B-selective, moderate NMDA receptor antagonist and potent spin trapping molecule for stroke","volume":"23","author":"Cho","year":"2000","journal-title":"Drug N. Perspect."},{"issue":"11","key":"10.1016\/j.bbr.2024.115173_bib125","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1161\/STROKEAHA.122.039649","article-title":"Nelonemdaz for patients with acute ischemic stroke undergoing endovascular reperfusion therapy: a randomized phase II trial","volume":"53","author":"Hong","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.bbr.2024.115173_bib126","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00406-019-01084-z","article-title":"Esketamine: a glimmer of hope in treatment-resistant depression","volume":"271","author":"Kaur","year":"2021","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"7","key":"10.1016\/j.bbr.2024.115173_bib127","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/phar.2707","article-title":"Safety and effectiveness of NMDA receptor antagonists for depression: a multidisciplinary review","volume":"42","author":"Moore","year":"2022","journal-title":"Pharmacother.: J. Hum. Pharmacol. Drug Ther."}],"container-title":["Behavioural Brain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432824003292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166432824003292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T08:29:47Z","timestamp":1723278587000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166432824003292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":127,"alternative-id":["S0166432824003292"],"URL":"https:\/\/doi.org\/10.1016\/j.bbr.2024.115173","relation":{},"ISSN":["0166-4328"],"issn-type":[{"value":"0166-4328","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting NMDA receptors with an antagonist is a promising therapeutic strategy for treating neurological disorders","name":"articletitle","label":"Article Title"},{"value":"Behavioural Brain Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbr.2024.115173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115173"}}